Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study - PubMed
4 hours ago
- #Hidradenitis Suppurativa
- #Secukinumab
- #IL-17 inhibitors
- Secukinumab, an IL-17 inhibitor, shows long-term effectiveness in treating moderate-to-severe Hidradenitis Suppurativa (HS).
- At week 52, 36.2% of patients achieved HiSCR, and 55.6% achieved IHS4-55 response criteria.
- Significant improvements were observed in skin pain (50.8% reduction) and quality of life (55.2% reduction).
- Patients in Hurley stage 3 had a lower likelihood of achieving IHS4-55 compared to Hurley stage 2.
- No new safety concerns were identified with long-term secukinumab use.
- The study supports secukinumab as a viable long-term treatment option for HS, including bio-experienced patients.